Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.31 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.31 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.30 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.30 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5204920 | 0.85 | DNM1 (0.37) | FAAHGGPS1PLA2G1BPLA2G2A | |
| SCHEMBL3313375 | 0.85 | DNM1 (0.37) | FAAHGGPS1PLA2G1BPLA2G2A | |
| SCHEMBL5207642 | 0.85 | DNM1 (0.37) | FAAHGGPS1PLA2G1BPLA2G2A | |
| SCHEMBL5202044 | 0.84 | KDM4E (0.34) | FAAHGGPS1PLA2G1BPLA2G2A | |
| SCHEMBL3320341 | 0.84 | KDM4E (0.34) | FAAHGGPS1PLA2G1BPLA2G2A | |
| Bromide SCHEMBL28902643 | 0.81 | DNM1 (0.36) | TSHRFAAHZDHHC20ZDHHC2GGPS1 | |
| Bromide SCHEMBL28340270 | 0.81 | DNM1 (0.36) | TSHRFAAHZDHHC20ZDHHC2GGPS1 | |
| Bromide SCHEMBL28340266 | 0.81 | DNM1 (0.36) | TSHRFAAHZDHHC20ZDHHC2GGPS1 | |
| Bromide SCHEMBL28340456 | 0.81 | DNM1 (0.36) | TSHRFAAHZDHHC20ZDHHC2GGPS1 | |
| SCHEMBL7771321 | 0.79 | TSHR (0.33) | TSHRFAAHZDHHC20ZDHHC2GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787570-B2 | ADMINISTERING AN AROMATIC OR HETEROAROMATIC SUBSTITUTED TERTIARYAMINE COMPOUND TO TREAT ATHEROSCLEROSIS, DYSLIPIDEMIA, AND OTHER CORONARY ARTERY DISEASES | PFIZER, INC. | 2004-09-07 | — | — | US | disclosed |
| US-20030191306-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-10-09 | — | — | US | disclosed |
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2001-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191306-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | TSHR 4014/4885FAAH 741/4885ZDHHC20 161/4885 |
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | TSHR 4014/4885FAAH 741/4885ZDHHC20 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.